Page last updated: 2024-09-05

erlotinib hydrochloride and Follicular Thyroid Carcinoma

erlotinib hydrochloride has been researched along with Follicular Thyroid Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cignarelli, M; Fabiano, A; La Macchia, O; Landriscina, M; Maddalena, F; Piscazzi, A	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Follicular Thyroid Carcinoma

Article	Year
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer research, 2010, Volume: 30, Issue:2 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured	2010

Article

Year

Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.

Anticancer research, 2010, Volume: 30, Issue:2

Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured

2010